Prot #BTCRC-BRE18-337: Phase 2 Trial with Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Big Ten Cancer Research Consortium BTCRC-BRE18-337

Project: Research project

Project Details

StatusActive
Effective start/end date1/21/20 → 1/21/26

Funding

  • Hoosier Cancer Research Network, Inc. (Prot #BTCRC-BRE18-337)
  • Pfizer Inc. (Prot #BTCRC-BRE18-337)